Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group”: [Ann Oncol 35 (2024) 588-606, (S092375342400111X), (10.1016/j.annonc.2024.04.005)]

M. F. Mosele, C. B. Westphalen, A. Stenzinger, F. Barlesi, A. Bayle, I. Bièche, J. Bonastre, E. Castro, R. Dienstmann, A. Krämer, A. M. Czarnecka, F. Meric-Bernstam, S. Michiels, R. Miller, N. Normanno, J. Reis-Filho, J. Remon, M. Robson, E. Rouleau, A. ScarpaC. Serrano, J. Mateo, F. André

    Résultats de recherche: Contribution à un journal!!Comment/debate

    Résumé

    The authors regret that in Table 8, the estimated prevalence of the BRAF V600E mutation in cholangiocarinoma should be 5%, not 50% as reported in the original publication. The corrected Table 8 is given below.

    langue originaleAnglais
    Pages (de - à)472
    Nombre de pages1
    journalAnnals of Oncology
    Volume36
    Numéro de publication4
    Les DOIs
    étatPublié - 1 avr. 2025

    Contient cette citation